Recent statistics show that congenital cardiovascular anomalies (“precocious heart disease”) have become the main type of birth defects in China’s newborns. The incidence of congenital heart disease in live births is about 8-12%, i.e. about 150-200,000 children born with congenital heart disease every year. The survey shows that precocious heart disease is the first factor causing neonatal death, seriously endangering the lives of children with precocious heart disease and affecting the long-term survival quality of children with precocious heart disease, becoming the number one “killer” threatening the health of children. Therefore, early detection, early diagnosis, formulation of appropriate treatment plans for children with different precocious diseases and timely treatment are especially important. For more than 20 years, the Department of Pediatric Cardiology of Beijing Anzhen Hospital has been dedicated to the diagnosis and treatment of children with precocious heart disease, and its technical level has always been in the leading position in China and enjoys a certain reputation in the international arena. The traditional treatment of precocious heart disease relies on surgery, which has been practiced clinically for decades, and is useful for common precocious heart diseases such as atrial septal defect, ventricular septal defect (commonly known as the “hole” between the ventricles and the atrium), arteriovenous ductus arteriosus, pulmonary valve stenosis, and Fallot valve stenosis. The majority of children with precardiac disease have been able to regain their health through surgery, and children with complex heart malformations have been able to prolong their lives and improve their quality of life through decompensated surgery. However, traditional surgical treatment requires opening the chest, in addition to possible anesthesia accidents, ischemia and reperfusion injury to various systems brought about by extracorporeal circulation, blood transfusion complications, cardiac arrhythmias, etc., in addition to the physical pain and psychological stress caused by the injury of opening the chest to the patient. Over the years, doctors have been working hard to find safe and effective ways to cure precordial disease with minimal trauma. As a result, the open-chest interventional treatment of precordial disease was born. After decades of technical exploration and device improvement, the international community has now gained mature experience in the treatment of common precordial diseases (atrial septal defect, ventricular septal defect, patent ductus arteriosus, pulmonary valve stenosis and other malformations) without opening the chest. The Department of Pediatric Cardiology of Anzhen Hospital, with many years of experience in the treatment of cardiovascular diseases in children and a solid foundation in surgery for preconditioning, successfully carried out balloon dilatation of pulmonary valve stenosis in 1987 and internal transcatheter occlusion treatment of atrial septal defect, ventricular septal defect and arteriovenous ductus arteriosus in 1995 in parallel with international practice. In 1997, the international application of the advanced Ampliflex In 1997, we started to apply the advanced Amplatzer blocker, which makes the treatment of atrial septal defect, ventricular septal defect (myocardial type), arteriovenous ductus arteriosus and other precordial diseases without opening the chest safer, easier and more effective. We have accumulated rich experience in the treatment of small infants and toddlers with small age, low weight, low growth, large defects and combined pulmonary hypertension, with high success rate and no serious complications or long-term residual deformities. The development of interventional therapy provides the best treatment option for patients with small membranous ventricular septal defects (less than 5 mm) who are reluctant to undergo surgery, but are afraid that the long-term presence of the defect may cause infective endocarditis. For atrial septal defects, ventricular septal defects, and arteriovenous malformations, a catheter is used to puncture the femoral vein at the root of the thigh and the femoral artery to establish a pathway along which a blocker is delivered to the site of the defect or malformation, and the defect (atrioventricular “hole” or arteriovenous duct) is closed. The procedure is completed by closing the defect (atrial “hole” or arterial duct). The procedure takes approximately 1-2 hours. For patients with pulmonary stenosis, the procedure is also successful when the catheter establishes a pathway to deliver a balloon to the stenotic pulmonary valve for pressure dilation and observes a satisfactory pressure drop after dilation. The advantages of interventional therapy are very significant and can be summarized as follows: 1, no open-chest cure for precordial disease, avoiding huge incisional trauma and pain 2, no general anesthesia, avoiding serious anesthetic complications 3, avoiding ischemia and reperfusion injury to multiple system organs by extracorporeal circulation in traditional surgery 4, no blood transfusion, avoiding blood transfusion allergy and infection with hepatitis virus and HIV 5, fast postoperative recovery, 24 hours after surgery 6.Good blocking effect, 24 hours after surgery, there is a significant improvement in heart function 7.Long-term observation of patients recover well, no case of blocker fracture off, the quality of life as normal 8.No open chest no scar, to avoid the knife to bring psychosocial pressure to the patient’s life learning process. In conclusion, interventional therapy has now become the first choice for the treatment of most patients with simple precordial diseases (atrial septal defect, patent ductus arteriosus, pulmonary valve stenosis, etc.), bringing the gospel of cure without opening the chest to the majority of patients with non-cyanotic precordial diseases.